tangotx.com - TNGX Income before deduction of interest, taxes and amortization

Graphic logo of Tango Therapeutics Inc (TNGX)

Tango Therapeutics (TNGX) is striving for a breakthrough in immuno-oncology despite a lack of profitability and a reliance on external financing. The underlying EBITDA confirms the current trend, where the indicator value stands at 0.00. While the bet on synthetic lethality for treating mutations reduces scientific risks, the absence of stable cash flow and the current stage of clinical trials create a certain level of uncertainty.

Profit before payment of interest, taxes and amortization: Tango Therapeutics (TNGX) for 11/23/2025 - 11/12/2026

Tango Therapeutics, Inc. - analytical breakdowns and key metrics (TNGX)

- market value and analyst target forecast:
Market Price Tango Therapeutics Corp|TNGX - Consensus Target
- issuer market value details:
Market Value Tango Therapeutics|TNGX - Enterprise Value
- book capitalization information:
Net Assets per Share Tango Therapeutics|TNGX - Company Book Value|Market Cap to Net Assets Ratio tangotx.com|TNGX - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Tango Therapeutics|TNGX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Tango Therapeutics Inc|TNGX - Company Debts|Debt to Book Value Ratio Tango Therapeutics|TNGX - Company Long-Term Debt|Short-Term Debt Tango Therapeutics|Critical Liquidity tangotx.com
- company profitability and valuation multiples indicators:
TNGX - Net Income|Future Net Profit Tango Therapeutics|TNGX - P/E Multiple|Future Price to Earnings Multiple tangotx.com|TNGX - PEG Multiple|Company Value to EBITDA Tango Therapeutics|TNGX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Tango Therapeutics|TNGX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth tangotx.com|TNGX - Earnings per share growth in current year|Net earnings per share change forecast for next year Tango Therapeutics
Analysis of all company metrics:Tango Therapeutics Corp - TNGX
Mass-produced product of Tango Therapeutics, Inc.

Tango Therapeutics (TNGX) develops precision oncology drugs using deep genetic cell analysis. Cash operating profit captures the actual daily liquidity inflow from core operations. This metric allows for the identification of hidden supply chain gaps prior to the publication of reports. Investors use this indicator to assess the balance between R&D expenditures and financial stability. The trend in cash operating profit confirms the viability of the innovative model.

Competitors of Tango Therapeutics (TNGX)

NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Iovance|Operating profit before deduction of amortization Immatics Biotechnologies (IMTX)|Profit before payment of interest, taxes and amortization Xencor, Inc. (XNCR)|Operating profit before deduction of amortization compasstherapeutics.com CMPX|Replimune - Operating profit before deduction of amortization|Operating profit EBITDA Lyell LYEL|IPHA - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology, Inc.) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS: Operating profit before deduction of amortization|kinetabio.com - Company profit before taxes, interest and amortization|NEXI: Operating profit EBITDA|Turnstone Biologics Corp. (TSBX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Operating profit before amortization HARP (Harpoon Therapeutics Corp)